IQ Proteomics
IQ Proteomics specializes in next-generation proteomic applications, offering optimized workflows for comprehensive and timely proteome characterization. Their services include discovery, targeted, and support proteomics, utilizing advanced technologies such as multiplexing with TMT™ reagents, PTMScan® technology, and real-time search MS3 or DIA acquisition. They focus on unbiased, proteome-wide, quantitative proteomics for drug target identification, biomarker discovery, and post-translational modifications, with a commitment to providing accurate, sensitive, and rapid quantification of biologically relevant targets. Established in 2015 and located near Boston, MA, IQ Proteomics has a proven track record of completing thousands of projects for major pharmaceutical and biotech companies.
Industries
Nr. of Employees
small (1-50)
Services
End-to-end discovery proteomics: project consultation and design, sample preparation, LC-MS data acquisition, data analysis, and delivery of QC metrics and annotated quantitative protein tables. Raw data and detailed methods available on request.
Custom targeted LC-MS assay development and execution for absolute and relative quantification, target engagement studies, and high-throughput sample analysis using targeted MS workflows and automated sample preparation.
Supplementary services including cell culture support, dedicated proteome informatics, instrument time (LC-MS acquisition of customer-prepared samples with flexible scheduling), and expedited processing options.
End-to-end discovery proteomics: project consultation and design, sample preparation, LC-MS data acquisition, data analysis, and delivery of QC metrics and annotated quantitative protein tables. Raw data and detailed methods available on request.
Custom targeted LC-MS assay development and execution for absolute and relative quantification, target engagement studies, and high-throughput sample analysis using targeted MS workflows and automated sample preparation.
Supplementary services including cell culture support, dedicated proteome informatics, instrument time (LC-MS acquisition of customer-prepared samples with flexible scheduling), and expedited processing options.
Expertise Areas
- Quantitative proteomics (discovery and targeted)
- Data-independent acquisition (DIA) workflows
- Isobaric multiplexed proteomics
- Post-translational modification analysis
Key Technologies
- High-resolution accurate-mass LC-MS/MS
- Data-independent acquisition (DIA)
- Data-dependent acquisition (DDA)
- Isobaric labeling for multiplexed quantitation
News & Updates
DIA acquisition via Orbitrap Astral provides deep coverage, faster project completion, and improved pricing, with notable figures of merit such as coverage of >10,000 proteins and a 5% median coefficient of variation.
The website has been completely redesigned to better showcase IQP's workflows, capabilities, and services.
IQP has onboarded an Orbitrap Astral with Tandem Neo high-throughput chromatography, broadening service offerings.
IQP will present posters on LC-MS applications for covalent inhibitor characterization.
IQP has moved to a purpose-built laboratory at 39 Grant St., Framingham, MA.
Study on understanding disease pathologies through localized biomolecular networks using enzymatic proximity techniques.
DIA acquisition via Orbitrap Astral provides deep coverage, faster project completion, and improved pricing, with notable figures of merit such as coverage of >10,000 proteins and a 5% median coefficient of variation.
The website has been completely redesigned to better showcase IQP's workflows, capabilities, and services.
IQP has onboarded an Orbitrap Astral with Tandem Neo high-throughput chromatography, broadening service offerings.
IQP will present posters on LC-MS applications for covalent inhibitor characterization.
IQP has moved to a purpose-built laboratory at 39 Grant St., Framingham, MA.
Study on understanding disease pathologies through localized biomolecular networks using enzymatic proximity techniques.